Edition:
United Kingdom

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,977.00GBp
17 Sep 2019
Change (% chg)

-- (--)
Prev Close
1,977.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
564,784
52-wk High
2,089.19
52-wk Low
1,491.50

Latest Key Developments (Source: Significant Developments)

Hikma Pharmaceuticals Raises FY Generics Revenue Guidance
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Hikma Pharmaceuticals PLC ::H1 OPERATING PROFIT ROSE 37 PERCENT TO 238 MILLION USD.H1 REVENUE ROSE 7 PERCENT TO 1.047 BILLION USD.HY GROUP CORE REVENUE OF $1,043 MILLION, UP 7%.HY GROUP CORE OPERATING PROFIT OF $246 MILLION, UP 15%.RAISING FULL YEAR EXPECTATIONS FOR GENERICS AND NOW EXPECT INJECTABLES TO BE TOWARDS HIGHER END OF OUR PREVIOUS FULL YEAR GUIDANCE RANGE.RAISING FULL YEAR EXPECTATIONS FOR GENERICS AND NOW EXPECT INJECTABLES TO BE TOWARDS HIGHER END OF OUR PREVIOUS FULL YEAR GUIDANCE.INTERIM DIVIDEND INCREASED 17% TO 14 CENTS PER SHARE.INCREASE IN FULL YEAR GUIDANCE REFLECTS CO'S CONFIDENCE FOR REMAINDER OF YEAR.NOW EXPECT GENERICS REVENUE TO BE IN RANGE OF $690 MILLION TO $720 MILLION FOR FULL YEAR.NOW EXPECT CORE OPERATING MARGIN TO BE IN RANGE OF 16% TO 18% FOR 2019.NOW EXPECT FY INJECTABLES REVENUE TO BE IN RANGE OF $870 MILLION TO $900 MILLION AND CORE OPERATING MARGIN TO BE IN RANGE OF 36% TO 38%.EXPECT CORE OPERATING MARGIN TO BE LOWER IN SECOND HALF IN INJECTABLES.EXPECT BRANDED REVENUE TO BE HIGHER IN SECOND HALF OF YEAR.CONTINUE TO EXPECT FULL YEAR BRANDED REVENUE GROWTH IN CONSTANT CURRENCY TO BE IN MID-SINGLE DIGITS.HY GROUP PROFIT BEFORE TAX WAS $226 MILLION (H1 2018: $141 MILLION).CONTINUE TO EXPECT CORE EFFECTIVE TAX RATE TO BE AROUND 21% FOR FULL YEAR IN 2019.NOW EXPECT GROUP CAPITAL EXPENDITURE FOR FULL YEAR TO BE AROUND $120 MILLION, AT LOWER END OF PREVIOUS GUIDANCE RANGE.  Full Article

Hikma Pharmaceutical And Civica Sign 5-Year Agreement For Injectable Medications
Tuesday, 23 Jul 2019 

July 23 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - HIKMA AND CIVICA RX SIGN LONG-TERM AGREEMENT.HIKMA PHARMACEUTICALS PLC - FIVE-YEAR AGREEMENT TO MANUFACTURE AND SUPPLY CIVICA'S GROWING MEMBERSHIP OF US HEALTH SYSTEMS.HIKMA PHARMACEUTICALS PLC - HIKMA WILL PRODUCE 14 ESSENTIAL STERILE INJECTABLE MEDICATIONS FOR CIVICA AS A PRIVATE LABEL DISTRIBUTOR.HIKMA PHARMACEUTICALS PLC - INITIAL SHIPMENTS OF PRODUCTS INCLUDED IN DEAL EXPECTED TO BEGIN BEFORE END OF 2019.  Full Article

Hikma Appoints Cynthia Schwalm As Director
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Hikma Pharmaceuticals PLC ::DIRECTORATE CHANGE.HIKMA BOARD APPOINTS CYNTHIA SCHWALM AS DIRECTOR.APPOINTMENT OF CYNTHIA SCHWALM AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR EFFECTIVE 1 JUNE 2019.  Full Article

Hikma Establishes Partnership With Melinta In MENA Region
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - HIKMA ESTABLISHES PARTNERSHIP WITH MELINTA IN MENA.HIKMA PHARMACEUTICALS PLC - HAS RIGHT OF FIRST NEGOTIATION FOR ALL OTHER PRODUCTS IN MELINTA'S PORTFOLIO AND PIPELINE IN MENA REGION.HIKMA- EXCLUSIVE LICENSE, SUPPLY, DISTRIBUTION AGREEMENT WITH MELINTA FORMELINTA'S INTRAVENOUS, ORAL FORMULATIONS OF BAXDELA ACROSS ALL MENA MARKETS.  Full Article

Hikma Pharmaceutical USA Launches Mitomycin For Injection
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - HIKMA LAUNCHES MITOMYCIN FOR INJECTION.HIKMA PHARMACEUTICALS PLC - HIKMA PHARMACEUTICALS USA INC LAUNCHED MITOMYCIN FOR INJECTION, USP, 20MG AND 40MG.  Full Article

Hikma Announces Agreement With Sciecure Pharma
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ANNOUNCES AGREEMENT WITH SCIECURE PHARMA.SCIECURE EXPECTS TO FILE THIS PRODUCT FOR APPROVAL WITH US FOOD AND DRUG ADMINISTRATION IN EARLY 2019.AGREEMENT PROVIDES CO EXCLUSIVE RIGHTS TO SELL ONE OF SCIECURE'S NICHE INJECTABLE ANTI-VIRAL MEDICINES ACROSS US FOR A MINIMUM OF EIGHT YEARS.DEAL HAS OPTION TO EXTEND PARTNERSHIP WITH SCIECURE FOR AN ADDITIONAL TWO YEARS.  Full Article

Joint Venture Between Gordon Brothers, New Mill Capital Acquired Three Buildings From Hikma Pharmaceuticals
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Hikma Pharmaceuticals PLC ::GORDON BROTHERS - JOINT VENTURE BETWEEN GORDON BROTHERS, NEW MILL CAPITAL ACQUIRED THREE BUILDINGS FROM HIKMA PHARMACEUTICALS IN EATONTOWN, NJ.  Full Article

Hikma Announces Agreement With Vectura
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Hikma Pharmaceuticals Plc ::HIKMA ANNOUNCES AGREEMENT WITH VECTURA.UPON SIGNING, HIKMA WILL MAKE AN UPFRONT PAYMENT OF $15 MILLION TO VECTURA.VECTURA WILL BE RESPONSIBLE FOR, AND FUND, INITIAL DEVICE AND FORMULATION DEVELOPMENT.DEAL FOR GLOBAL DEVELOPMENT AND COMMERCIALISATION OF GENERIC VERSIONS OF GSK'S ELLIPTA PORTFOLIO.UPON TRANSFER OF 1ST PRODUCT TO CO'S MANUFACTURING FACILITY, WILL MAKE $5 MILLION MILESTONE PAYMENT TO VECTURA.THEREAFTER, HIKMA WILL MAKE MILESTONE PAYMENTS OF UP TO $75 MILLION AT VARIOUS STAGES OF DEVELOPMENT.VECTURA WILL CONTRIBUTE UP TO $70 MILLION TOWARDS HIKMA'S DEVELOPMENT ACTIVITIES FOR PORTFOLIO.HIKMA PHARMACEUTICALS - VECTURA'S CONTRIBUTION TO BE MADE THROUGH REDUCED PROFIT SHARE MECHANISM FOLLOWING COMMERCIAL LAUNCH OF FIRST PRODUCT.  Full Article

Hikma Pharmaceuticals Raises Guidance For Injectables, Generics Businesses For Full Year
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - Hikma Pharmaceuticals PLC ::H1 OPERATING PROFIT 174 MILLION USD VERSUS 113 MILLION USD YEAR AGO.H1 REVENUE 989 MILLION USD VERSUS 895 MILLION USD YEAR AGO.INTERIM DIVIDEND 0.12 USDPER SHARE.GUIDANCE RAISED FOR INJECTABLES AND GENERICS BUSINESSES AND REITERATED FOR BRANDED BUSINESS.RAISE GUIDANCE FOR BOTH OUR INJECTABLES AND GENERICS BUSINESSES FOR FULL YEAR.NOW EXPECT FULL YEAR INJECTABLES REVENUE TO BE IN RANGE OF $775 MILLION TO $825 MILLION.EXPECT GENERICS FULL YEAR REVENUE TO BE IN RANGE OF $600 MILLION TO $650 MILLION.EXPECT BRANDED REVENUES TO BE HIGHER IN SECOND HALF OF YEAR.EXPECT FULL YEAR BRANDED REVENUE GROWTH IN CONSTANT CURRENCY TO BE IN MID-SINGLE DIGITS.DON'T EXPECT SAME DEMAND FOR SOME OF OUR INJECTABLE PRODUCTS TO CONTINUE INTO 2019.NOT CLEAR HOW LONG INJECTABLE OPIOIDS SHORTAGES WILL PERSIST; DON'T EXPECT TO SEE SAME LEVEL OF DEMAND CONTINUE INTO 2019.MENA INJECTABLES REVENUE WAS $51 MILLION IN H1 2018, UP 46%.IN H1 2018, GLOBAL INJECTABLES REVENUE INCREASED BY 14% TO $414 MILLION.CONTINUE TO EXPECT GROUP CAPITAL EXPENDITURE IN RANGE OF $120 MILLION TO $140 MILLION IN 2018.  Full Article

Acorda Updates On Litigation With Mylan, Teva, West-Ward Pharma & Hikma
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS - UPDATES ON LITIGATION WITH MYLAN, TEVA, WEST-WARD PHARMACEUTICALS INTERNATIONAL & HIKMA PHARMACEUTICALS USA.ACORDA THERAPEUTICS - TERMS OF SETTLEMENT AGREEMENT WITH MYLAN AND INTERIM AGREEMENTS WITH TEVA AND HIKMA ARE OTHERWISE CONFIDENTIAL.ACORDA THERAPEUTICS - MYLAN WILL BE PERMITTED TO MARKET ITS GENERIC VERSION OF AMPYRA IN U.S. SOMETIME IN 2025/EARLIER AS PER A CONDITIONED SETTLEMENT WITH CO.ACORDA THERAPEUTICS - SIGNED INTERIM AGREEMENT WITH TEVA CONCERNING PATENT LITIGATION RELATING TO AMPYRA THAT ADDRESSES PERIOD OF TIME UNTIL AUG 31.ACORDA THERAPEUTICS SAYS ALSO SIGNED INTERIM AGREEMENT WITH HIKMA CONCERNING THEIR PATENT LITIGATION RELATING TO AMPYRA - SEC FILING.  Full Article

RPT-GRAPHIC-FTSE 100's changing face: A trip down memory lane

LONDON, Sept 10 Marks & Spencer's exit from the FTSE 100 underlines how times have changed since the blue-chip index was launched in 1984, when it was dominated by British companies including household names like M&S, Cadbury and House of Fraser.